In Iceland, 91% of people who had recovered from Covid-19 developed detectable antibodies A good number of people have been reinfected by SARS-Cov-2, which includes individuals in Hong Kong, U.S., and Italy. This has resulted in a panic over the future course of the pandemic.
One of the best ways to tackle this new coronavirus is partial herd immunity; this can help slow its spread, as the numbers of cases keep increasing globally. Since the vaccine is seen as the game-changer in fighting against the pathogen, this also relies on inducing long-lasting antibody reactions in inoculated individuals.
The question is, what if immunity declines, plunging humanity into an endless cycle of relapses? This is really a nightmare.
Luckily for us, things may not be that bad. So far, there have been few cases of confirmed reinfections, which indicate that they may be uncommon. According to some doctors, most relapses will be milder than the first infection. The impact of the virus will be determined by our body’s ability to fight it, for instance, through the development of suitable so-called T-cells.
You can also read: Aberdeen Residents Warned not to Feed the Gulls
A very important way to evaluate the risk of reinfection is determining the numbers of individuals that have antibodies and how long they last. According to some experts, only people that suffer the worst Covid-19 cases develop immunity that is sizeable and protracted enough to create adequate antibodies.
If this is the fact, the fortunate ones who don’t have the worst symptoms such as young adults and kids will be more prone to reinfection. According to a recent study conducted in Iceland on the pandemic, there has been evidence to dismiss such fears.
In Iceland serum samples collected from 30,576 people have been checked by the researchers, different kinds of antibody testing were used since different methods often give conflicting results. According to the central findings, only 91.1% of 1,797 people who had recovered from the virus developed detectable levels of antibodies.